Why are investors looking for Cost Plus Drug Company IPO?

3 min read | February 23, 2022 01:30 AM AEDT | By Raza Naqvi

Why are investors looking for Cost Plus Drug Company IPO plans?

According to a 2021 Gallup poll, around 18 million people in the United States can't afford at least one prescribed medicine due to a high cost. Meanwhile, one out of 10 people skipped doses of their prescribed medicines to reduce expenditure.

Mark Cuban Cost Plus Drug Company offers 100 life-saving generic drugs at a low cost. According to reports, some of the medicines provided by MCCPDC are ten times cheaper than those sold by other stores.

As the healthcare sector draws an increased investors' attention after the breakout of the coronavirus pandemic, it seems that Cost Plus Drug Company is attracting potential investors due to this reason.

Also Read: What is PayMongo and why is it grabbing attention?

Also, investing in IPOs brings the prospect of getting higher returns at the time of public debut. However, investors don't always earn profit by investing in pre-IPO stocks.

Bottom line

It is uncertain if Cost Plus Drug IPO will happen. The company has not revealed any public debut plans.

Mark Cuban Cost Plus Drug Company provides cheaper drugs by removing insurance plans and intermediaries.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.